CHA
AMPE

Cooper/Haims Advisors’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Cooper/Haims Advisors’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33
Closed -$17K – 92
2021
Q1 		$17K Buy
+33
New +$17K 0.01% 79
2020
Q3 		– Sell
-43
Closed -$8K – 60
2020
Q2 		$8K Buy
+43
New +$7.15K 0.01% 54

Other funds holding AMPE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Willis Investment Counsel Gainesville, Georgia $1.83B AUM 15.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return

Cooper/Haims Advisors's AMPE Position: Q2 2021 in Review

Cooper/Haims Advisors sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q2 2021, closing a stake of 33 shares — an estimated $17K sold.

Cooper/Haims Advisors first reported a position in AMPE in Q2 2020 and held it in 2 quarters. The position peaked at $17K in Q1 2021. 128 funds tracked by Wall St. Rank hold AMPE as of Q2 2021.

  • Cooper/Haims Advisors reported no remaining Ampio Pharmaceuticals Inc. position as of Q2 2021 after selling out during the quarter.
  • Cooper/Haims Advisors sold 33 Ampio Pharmaceuticals Inc. shares in Q2 2021, an estimated $17K.
  • Cooper/Haims Advisors first reported a position in Ampio Pharmaceuticals Inc. in Q2 2020 and held it in 2 quarters.
  • Cooper/Haims Advisors's Ampio Pharmaceuticals Inc. position peaked at $17K in Q1 2021.
  • 128 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q2 2021.

Based on Cooper/Haims Advisors's 13F filing for Q2 2021, filed 4 Aug 2021.